Instil Bio, Inc. (TIL)
| Market Cap | 739.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -211.46M |
| Shares Out | 129.69M |
| EPS (ttm) | -1.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300,531 |
| Open | 6.15 |
| Previous Close | 6.36 |
| Day's Range | 5.60 - 6.21 |
| 52-Week Range | 3.90 - 23.68 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 24.74 (+334.0%) |
| Earnings Date | Aug 10, 2022 |
About TIL
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TIL stock is "Buy." The 12-month stock price forecast is 24.74, which is an increase of 334.04% from the latest price.
News
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor M...
DALLAS, May 27, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for ...
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
Presentation to highlight correlates of response to TIL product attributes and elements of Instil Bio's cell therapy data analytics and computational platform Presentation to highlight correlates of res...
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
DALLAS, May 16, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TI...
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
DALLAS, March 02, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies fo...
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies f...
Instil Bio to Present at Upcoming Investor Conferences in November
DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response
Instil Bio to Present at the Jefferies Virtual Healthcare Conference
DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
IPO in March 2021 raising $368M in gross proceeds
At a Recent Cancer Research Conference, Instil Bio Stole the Show
The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma...
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association...
67% overall response rate and 19% complete response rate in 21 patients
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additio...
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...
Three Biotechs and a Marijuana Lender Begin Trading. Here's How They Did.
Connect Biopharma, Finch Therapeutics, Instil Bio, and AFC Gamma made their public-equity market debuts Friday.
Instil Bio Announces Pricing of Upsized Initial Public Offering
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...